Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening-the EarLy Surveillance for Autoimmune diabetes (ELSA) study.

Autor: Quinn LM; Institute of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Birmingham, UK., Dias RP; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.; Department of Paediatric Endocrinology, Birmingham Women and Children's Hospital, Birmingham, UK., Greenfield SM; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK., Richter AG; Clinical Immunology Service, University of Birmingham, Birmingham, UK., Garstang J; Birmingham Community Healthcare NHS Trust, Birmingham, UK.; School of Nursing, University of Birmingham, Birmingham, UK., Shukla D; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.; Clinical Research Network, Lead for Primary Care (CRN West Midlands), National Institute for Health and Care Research, Royal Wolverhampton Hospital, Wolverhampton, UK., Acharjee A; Institute of Cancer and Genomic Medicine, University of Birmingham, Birmingham, UK.; MRC Health Data Research UK (HDR UK), Birmingham, UK.; Institute of Translational Medicine, University Hospitals Birmingham NHS, Birmingham, UK.; Centre for Health Data Research, University of Birmingham, Birmingham, UK., Gkoutos G; Institute of Cancer and Genomic Medicine, University of Birmingham, Birmingham, UK.; MRC Health Data Research UK (HDR UK), Birmingham, UK.; Institute of Translational Medicine, University Hospitals Birmingham NHS, Birmingham, UK.; Centre for Health Data Research, University of Birmingham, Birmingham, UK., Oram R; University of Exeter, Exeter, UK., Faustini S; Clinical Immunology Service, University of Birmingham, Birmingham, UK., Boiko O; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK., Litchfield I; Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK., Boardman F; Warwick Applied Health, Warwick Medical School, Warwick, UK., Zakia F; Community Connexions, Birmingham Community Healthcare NHS Foundation Trust, Birmingham, UK., Burt C; Community Connexions, Birmingham Community Healthcare NHS Foundation Trust, Birmingham, UK., Connop C; INVOLVE co-applicant, Birmingham, UK., Lepley A; INVOLVE co-applicant, Birmingham, UK., Gardner C; INVOLVE co-applicant, Birmingham, UK., Dayan C; Division of Infection and Immunity, School of Medicine, University of Cardiff, Cardiff, UK., Barrett T; Institute of Cancer and Genomic Medicine, University of Birmingham, Birmingham, UK., Narendran P; Institute of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Birmingham, UK.; Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK.
Jazyk: angličtina
Zdroj: Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2024 Dec 02, pp. e15490. Date of Electronic Publication: 2024 Dec 02.
DOI: 10.1111/dme.15490
Abstrakt: Aim: The EarLy Surveillance for Autoimmune (ELSA) study aims to explore the feasibility and acceptability of UK paediatric general population screening for type 1 diabetes.
Methods: We aim to screen 20,000 children aged 3-13 years for islet-specific autoantibodies through dried blood spot sample collection at home, hospital or community settings. Children with two or more autoantibodies are offered metabolic staging via oral glucose challenge testing. Feasibility assessments will compare recruitment modalities and uptake according to demographic factors (age, gender, ethnicity, level of deprivation and family history of diabetes) to determine optimal approaches for general population screening. The study is powered to identify 60 children (0.3%) with type 1 diabetes (stage 1-3). Parents are invited to qualitative interviews following ELSA completion (child screened negative or positive, single autoantibody or multiple, stage 1-3) to share their screening experience, strengths of the programme and any areas for improvement (acceptability assessments). Parents who decline screening or withdraw from participation are invited to interview to explore any concerns. Finally, we will interview professional stakeholders delivering the ELSA study to explore barriers and facilitators to implementation.
Conclusion: Early detection of type 1 diabetes allows insulin treatment to be started sooner, avoids diagnosis as an emergency, gives families time to prepare and the opportunity to benefit from future prevention trials and treatments. ELSA will provide essential feasibility and acceptability assessments for UK general population screening to inform a future national screening programme for paediatric type 1 diabetes.
(© 2024 The Author(s). Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.)
Databáze: MEDLINE
Externí odkaz: